Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients.
Schüler K, Bethmann D, Kaufhold S, Hartung C, Stückrath K, Lantzsch T, Uleer C, Hanf V, Peschel S, John J, Pöhler M, Buchmann J, Bürrig KF, Weigert E, Thomssen C, Kantelhardt EJ, Vetter M. Schüler K, et al. Among authors: vetter m. Diagnostics (Basel). 2022 Oct 18;12(10):2527. doi: 10.3390/diagnostics12102527. Diagnostics (Basel). 2022. PMID: 36292215 Free PMC article.
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N. Kantelhardt EJ, et al. Among authors: vetter m. BMC Cancer. 2011 Apr 16;11:140. doi: 10.1186/1471-2407-11-140. BMC Cancer. 2011. PMID: 21496284 Free PMC article. Clinical Trial.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N. Jacobs VR, et al. Among authors: vetter m. Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9. Breast Cancer Res Treat. 2013. PMID: 23568480 Clinical Trial.
The prevalence of estrogen receptor-negative breast cancer in Ethiopia.
Kantelhardt EJ, Mathewos A, Aynalem A, Wondemagegnehu T, Jemal A, Vetter M, Knauf E, Reeler A, Bogale S, Thomssen C, Stang A, Gemechu T, Trocchi P, Yonas B. Kantelhardt EJ, et al. Among authors: vetter m. BMC Cancer. 2014 Nov 29;14:895. doi: 10.1186/1471-2407-14-895. BMC Cancer. 2014. PMID: 25433805 Free PMC article.
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ. Bernhardt S, et al. Among authors: vetter m. Breast Cancer Res. 2017 Oct 11;19(1):112. doi: 10.1186/s13058-017-0905-7. Breast Cancer Res. 2017. PMID: 29020998 Free PMC article. Clinical Trial.
Comparison of six breast cancer classifiers using qPCR.
Berchtold E, Vetter M, Gündert M, Csaba G, Fathke C, Ulbrich SE, Thomssen C, Zimmer R, Kantelhardt EJ. Berchtold E, et al. Among authors: vetter m. Bioinformatics. 2019 Sep 15;35(18):3412-3420. doi: 10.1093/bioinformatics/btz103. Bioinformatics. 2019. PMID: 30759193
451 results